Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Analysts
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $56.08, exceeding its current share price of $41.70. While recent analyst actions were mixed, including Guggenheim raising its target to $100 and Cantor Fitzgerald cutting its target to $61, the overall sentiment remains positive. The company reported a quarterly loss of $0.94 per share, beating expectations, but revenue of $0.02 million missed estimates significantly.
Celldex Therapeutics, Inc. $CLDX Shares Acquired by Bank of America Corp DE
Bank of America Corp DE significantly increased its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 70.8% in the first quarter, now owning 708,647 shares valued at $22.5 million. This comes as Celldex, a clinical-stage biopharmaceutical company, reported a smaller-than-expected quarterly loss of $0.94 per share. Analysts maintain a "Moderate Buy" consensus rating for CLDX, with an average price target of $55.46.
Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake
Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has disclosed a beneficial ownership of 6.78% in Celldex Therapeutics, Inc. This ownership translates to shared voting and dispositive power over 5,322,908 shares of Celldex's common stock. The filing, a SCHEDULE 13G/A, indicates that no single entity among the reporting persons holds sole voting or dispositive power over these shares.
T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G
T. Rowe Price Associates has disclosed a 6.0% beneficial ownership stake in Celldex Therapeutics Inc. (CLDX) through a Schedule 13G filing. The firm reported holding 4,686,187 shares of common stock, with sole voting power over 4,683,226 shares and sole dispositive power over all 4,686,187 shares. Despite the disclosure, T. Rowe Price Associates explicitly states that this report should not be interpreted as an admission of beneficial ownership.
Celldex Therapeutics (CLDX) Reported Wider Losses, Is It Still Undervalued?
Celldex Therapeutics (CLDX) recently reported wider losses and lower revenue for Q2 and H1 2026, yet its stock has seen significant recent gains. While the company trades at a 4.9x Price-to-Book multiple, suggesting it's overvalued compared to peers, a Discounted Cash Flow (DCF) model indicates it's trading 61.1% below its estimated intrinsic value of $113.93 per share. Investors are left to weigh the company's widening losses and P/B valuation against its strong recent stock performance and potential future cash flow value.
Sei Investments Co. Purchases Shares of 38,152 Celldex Therapeutics, Inc. $CLDX
Sei Investments Co. recently acquired a new stake of 38,152 shares in Celldex Therapeutics, Inc., valued at approximately $1.21 million. This comes as several other hedge funds have also adjusted their positions in the biopharmaceutical company. Celldex Therapeutics reported better-than-expected quarterly earnings and has received new price targets from analysts, with a consensus of "Moderate Buy."
Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress
Celldex Therapeutics (CLDX) reported wider Q2 and first-half losses totaling US$73.5 million and US$152.19 million, respectively, yet its stock rose by 10.7%. This increase is attributed to positive Phase 1 data for bispecific antibody CDX-622 and continued Phase 3 progress for barzolvolimab, despite minimal revenue. The company's investment narrative hinges on the success of its barzolvolimab Phase 3 program and broader allergy and immunology pipeline justifying its premium valuation despite growing losses and funding needs.
Quantinno Capital Management LP Buys 42,158 Shares of Celldex Therapeutics, Inc. $CLDX
Quantinno Capital Management LP significantly increased its stake in Celldex Therapeutics (NASDAQ:CLDX) by 178.7% in the first quarter, purchasing an additional 42,158 shares to own a total of 65,744 shares valued at $2.09 million. This move comes as institutional investors continue to adjust their positions in the biopharmaceutical company, which has seen generally positive analyst sentiment, with an average price target of $55.46 and a "Moderate Buy" consensus rating. Celldex Therapeutics recently reported a quarterly loss that beat estimates but fell short on revenue, while its stock opened near its 52-week high.
Assenagon Asset Management S.A. Buys 642,171 Shares of Celldex Therapeutics, Inc. $CLDX
Assenagon Asset Management S.A. significantly increased its stake in Celldex Therapeutics, purchasing an additional 642,171 shares, bringing its total to 788,696 shares valued at $29.35 million. This move comes as several other institutional investors also adjusted their positions in the biopharmaceutical company. Analysts maintain a "Moderate Buy" rating for Celldex, with updated price targets from Guggenheim ($100) and Wells Fargo ($72).
First Trust Advisors LP Has $2.17 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX
First Trust Advisors LP significantly increased its stake in Celldex Therapeutics, adding 78.7% more shares in the first quarter to reach a total holding of $2.17 million. Other institutional investors also raised or initiated positions. Despite missing revenue estimates, Celldex Therapeutics reported a narrower-than-expected quarterly loss, and analysts maintain a "Moderate Buy" rating with an average price target of $55.46.
Celldex Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.07, Implies 40% Upside
The average 12-month price target for Celldex Therapeutics, Inc. (CLDX) stock has been raised from $57.07 to $58.07 by 15 analysts, with individual forecasts ranging from $38 to $100 per share. This new target suggests a potential upside of approximately 40% based on the August 6th closing price. The consensus analyst rating remains a "Buy," with 15 out of 16 analysts recommending a Buy and 1 recommending a Hold.
Celldex Therapeutics, Inc. 2026: Revenue $22K, EPS ($0.94) — 10-Q Summary
Celldex Therapeutics, Inc. reported its financial results for the quarter ended 2026, with revenue of $22K and a diluted loss per share of ($0.94), resulting in a net loss of ($73.5M) due to ongoing investments in trials and manufacturing. The company highlighted clinical milestones, including completed enrollment for Phase 3 CSU trials, initiation of Phase 3 for ColdU/SD, and advancements in its bispecific platform candidate CDX-622. R&D spending significantly increased, primarily driven by barzolvolimab-related activities and scaling of commercial manufacturing.
Celldex Reports Second Quarter Financial Results and Provides Corporate Update
Celldex reported its second-quarter 2026 financial results, highlighting ongoing Phase 3 studies for barzolvolimab in chronic spontaneous urticaria with topline data expected in Q3/Q4 2026, and actively enrolling patients for cold urticaria and symptomatic dermographism studies. The company also announced positive Phase 1 results for its bispecific antibody CDX-622 and is advancing its development into additional indications while discontinuing the Phase 2 prurigo nodularis study due to not meeting efficacy endpoints. Celldex's cash position stands at $717.6 million, projected to fund operations through 2028 despite an increased net loss compared to the previous year.
Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 million
Celldex reported a wider net loss of $
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $0.0M
Celldex Therapeutics, Inc. (CLDX) announced its Q2 revenue was $0.0M, as detailed in an earnings flash from MarketScreener. The company, a clinical-stage biotechnology firm, focuses on developing antibody-based therapeutics for inflammatory, allergic, autoimmune, and other diseases. Recent news also included adjustments to price targets by Morgan Stanley and the discontinuation of a Phase 2 study for Barzolvolimab in Prurigo Nodularis.
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Celldex Therapeutics (CLDX) reported a Q2 loss of $0.94 per share, which was better than the Zacks Consensus Estimate of a $1.04 loss, but missed revenue estimates significantly, posting only $0.02 million against an expectation of $0.73 million. Despite the revenue miss, the company's shares have risen over 51% year-to-date, outperforming the S&P 500, and currently hold a Zacks Rank #2 (Buy).
Dimensional Fund Advisors LP Has $33.60 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX
Dimensional Fund Advisors LP significantly increased its stake in Celldex Therapeutics, adding over 400,000 shares to hold 1.06 million shares valued at $33.6 million. Despite Celldex reporting a larger-than-expected quarterly loss and negligible revenue, analysts maintain a "Moderate Buy" rating with an average price target of $54.62. Several other institutional investors have also adjusted their positions in the biopharmaceutical company.
Celldex Therapeutics earnings up next as Phase III data looms By Investing.com
Celldex Therapeutics is set to report its second-quarter earnings, with investors focusing on the timing of topline data from its pivotal Phase III EMBARQ-CSU studies, expected in September to October. Analysts project a loss of $1.06 per share on revenue of $803,000, and Wall Street maintains a strong-buy consensus despite a recent Phase 2 trial failure. The earnings call will also address resource allocation after the discontinuation of the prurigo nodularis study and the company's cash position given its substantial burn rate.
Celldex Therapeutics stock hits 52-week high at $40.30
Celldex Therapeutics (CLDX) stock hit a new 52-week high of $40.30, with shares up 73% in the past six months and 86.85% over the past year, reflecting strong investor confidence. Despite this surge, InvestingPro data suggests the stock is currently overvalued. The company faces mixed news, including the discontinuation of a Phase II study for barzolvolimab in prurigo nodularis, leading to a lowered price target from Canaccord, but also positive outlooks for its chronic spontaneous urticaria trial from Guggenheim and UBS.
Celldex Therapeutics stock hits 52-week high at $40.30 By Investing.com
Celldex Therapeutics stock reached a 52-week high of $40.30, showcasing significant investor confidence with an 86.85% increase over the past year. Despite this surge and a market capitalization of $3.16 billion, InvestingPro data suggests the stock is currently overvalued. The company faces mixed news, including the discontinuation of a Phase II study for prurigo nodularis, but positive outlooks for a chronic spontaneous urticaria trial and reiterated Buy ratings from some analysts.
Celldex Therapeutics (CLDX) After Phase 2 Trial Results As Valuation Questions Come Into Focus
Celldex Therapeutics (CLDX) is under scrutiny following its Phase 2 clinical trial results for prurigo nodularis. The stock has seen significant momentum with strong share price returns over the last year, leading to questions about its valuation. While it trades at a discount compared to direct peers based on price-to-book ratio, it appears expensive against the broader US biotech industry, prompting investors to assess whether the market is overly cautious or conservative about its potential.
Celldex Therapeutics Inc (CLDX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Celldex Therapeutics Inc (CLDX), noting its current valuation score of 6.88, which ranks 244 out of 385 in the Biotechnology & Medical Research industry. The company's P/E ratio is -8.92, indicating a position between its recent high and low P/E values. The analysis also states that relevant data for P/B, P/S, and P/CF ratios have not been disclosed by the company.
Celldex Therapeutics Inc (CLDX) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial analysis of Celldex Therapeutics Inc (CLDX), highlighting its current financial score of 5.70, which ranks 328 out of 385 in the Biotechnology & Medical Research industry. The company's financial status is stable with low operating efficiency, marked by a significant year-over-year decrease in quarterly revenue and net profit. The analysis breaks down various financial dimensions including cash and cash equivalents, total assets, total liabilities, and free cash flow.
CLDX|Celldex Therapeutics Inc|Price:35.660|Chg%:+0.380
This article provides a comprehensive stock analysis of Celldex Therapeutics Inc (CLDX) by TradingKey, detailing its stock score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. The company's fundamentals are considered healthy with significant growth potential, and it is deemed fairly valued within the Biotechnology & Medical Research industry. Analysts have rated CLDX as a Buy, with expectations for the stock price to trend upward in the medium term.
Celldex Therapeutics Inc (CLDX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Celldex Therapeutics Inc (CLDX), listing major shareholders such as Wellington Management Company, LLP and BlackRock Institutional Trust Company, N.A., along with their respective holdings and proportions. It also breaks down shareholder types, institutional shareholding trends over several quarters, and recent shareholder activities. Additionally, the article identifies related ETFs that hold CLDX stock.
Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Celldex Therapeutics Inc (CLDX) has an earnings forecast score of 8.50, ranking 106th in the Biotechnology & Medical Research industry, with an average price target of $53.00. Analysts largely recommend a "Buy" for CLDX, with 16 analysts providing ratings. The company's expected revenue for the next quarter is $954.44K, and EPS for the next quarter is projected at USD -1.06.
Celldex Therapeutics, Inc. Revenue Breakdown – DUS:TCE2
Celldex Therapeutics, Inc. (DUS:TCE2) generated €1.32 million in revenue last year, primarily from its "Novel Therapeutics for Human Health Care" segment, a significant decrease from €6.78 million in the previous year. The United States was the company's largest regional contributor, matching the segment's revenue.
Celldex Therapeutics (CLDX) Stock May Trade At A Premium After A 59% Run
Celldex Therapeutics (CLDX) stock has seen a significant 59.5% return over the past year, leading to a valuation that appears expensive when considering market multiples and P/B ratio. The company's P/B ratio of 6.1x is higher than the broader biotech industry average, indicating a premium valuation despite it being a clinical-stage biotech without current free cash flow. Investors need to weigh the potential of its clinical pipeline against the current high expectations embedded in its stock price and decide if the premium is justified by future progress and funding.
CELLDEX THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $70 FROM $78
Leerink Partners has decreased its target price for Celldex Therapeutics Inc. from $78 to $70. This change was reported by Reuters two days prior to the crawl date, indicating a potential re-evaluation of the company's financial outlook by the analyst firm.
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
This article provides an update on several biopharma companies. Summit Therapeutics has released new data for its cancer immunotherapy ivonescimab, which shows improved survival rates in lung cancer patients, addressing investor skepticism. Celldex Therapeutics' autoimmune drug barzolvolimab failed a mid-stage trial for prurigo nodularis but is still anticipated to show positive results in a late-stage study for chronic spontaneous urticaria. Other updates include Gilead and Merck's new once-weekly HIV tablet data, Lupin spinning off two cancer drug prospects into a new startup, and Jupiter Neuroscience acquiring partial rights to an experimental psychedelic from PharmAla Biotech.
Stifel Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $68
Stifel has maintained its Buy rating on Celldex Therapeutics (CLDX.US) and reiterated a target price of $68. This indicates continued confidence from Stifel in the company's performance and future prospects.
Celldex Stands By Barzolvolimab in CSU After Prurigo Nodularis Miss
Celldex maintains confidence in its drug barzolvolimab for Chronic Spontaneous Urticaria (CSU) despite a recent trial failure in Prurigo Nodularis. The company's stance follows a previous study miss for the drug in August 2025. This article highlights Celldex's continued commitment to barzolvolimab for CSU.
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study
Celldex Therapeutics has discontinued its Phase 2 clinical trial for barzolvolimab in prur
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
Celldex Therapeutics announced it is discontinuing the development of barzolvolimab for prurigo nodularis (PN) after the drug failed to meet primary and secondary endpoints in a Phase 2 trial. Despite the drug effectively depleting mast cells, it did not significantly improve itch or skin lesions in PN patients, suggesting mast cells may not be the primary driver of the condition's symptoms. The company will now focus its resources on ongoing late-stage urticaria programs, with top-line data for chronic spontaneous urticaria expected in September-October.
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: A Biotech Gem with 64% Potential Upside
Celldex Therapeutics, Inc. (CLDX) is a biopharmaceutical company specializing in treatments for inflammatory, allergic, and autoimmune diseases, boasting a market cap of $2.78 billion. Despite currently being unprofitable, indicated by a negative Forward P/E ratio, analysts forecast a 64.31% potential upside with an average target price of $58.20. The company's lead drug candidates, Barzolvolimab and CDX-622, are addressing significant unmet medical needs, positioning Celldex as a growth opportunity within the biotech sector, albeit with inherent financial risks typical of developmental-stage firms.
Celldex stock falls after phase 2 trial misses key endpoints By Investing.com
Celldex Therapeutics shares dropped 13% after the company announced that its Phase 2 study of barzolvolimab for prurigo nodularis failed to meet its primary and key secondary endpoints. Despite demonstrating profound mast cell depletion, the drug did not improve itch or skin lesions compared to placebo, leading Celldex to discontinue the study for this indication. However, the company will continue to advance barzolvolimab for other conditions, with Phase 3 data for chronic spontaneous urticaria expected in late 2026.
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Celldex Therapeutics reported that its Phase 2 study of barzolvolimab in prurigo nodularis (PN) did not meet primary or key secondary efficacy endpoints, despite showing profound mast cell depletion. The company is discontinuing the PN study, concluding that mast cells may not be a primary driver of PN symptoms. Celldex remains focused on barzolvolimab's development for other mast cell-driven conditions, with Phase 3 CSU topline data expected in Q3 2026.
Celldex Drug Depleted Mast Cells but Did Not Ease PN Itch
Celldex (NASDAQ: CLDX) announced that its Phase 2 study of barzolvolimab for prurigo nodularis (PN) failed to meet its primary and key secondary endpoints, despite successfully depleting mast cells. The company is discontinuing the PN program based on these results, which suggested that mast cell depletion did not improve itch or skin lesions in PN patients. Barzolvolimab will continue in Phase 3 studies for chronic spontaneous urticaria (CSU), symptomatic dermographism, and cold urticaria, with CSU topline data expected in September/October 2026.
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Celldex announced that its Phase 2 study of barzolvolimab in prurigo nodularis did not meet its primary and key secondary efficacy objectives, despite showing profound mast cell depletion. The company will discontinue this specific study but remains focused on other indications, expecting Phase 3 CSU topline data in Q3 2026. Barzolvolimab demonstrated a favorable safety profile consistent with prior studies.
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Celldex reported that its Phase 2 study of barzolvolimab for prurigo nodularis (PN) did not meet its primary or key secondary efficacy endpoints, leading the company to discontinue the study for this indication. Despite profound mast cell depletion in PN patients, there was no improvement in itch or skin lesions compared to placebo, suggesting mast cells may not be a primary driver of PN symptoms. Celldex will continue to focus on barzolvolimab for chronic spontaneous urticaria (CSU), symptomatic dermographism (SD), and cold urticaria (ColdU), with Phase 3 CSU data expected in late 2026.
Celldex to stop skin disease study after trial setback
Celldex Therapeutics announced it would discontinue development of its experimental drug barzolvolimab for prurigo nodularis after it failed to meet primary and secondary goals in a mid-stage study. This setback sent the company's shares down over 7% in extended trading. Despite the drug effectively reducing mast cells, patients did not show improvement in symptoms, suggesting mast cells might not be the primary driver of the skin condition.
Guggenheim raises Celldex stock price target on trial outlook By Investing.com
Guggenheim has increased its price target for Celldex Therapeutics (NASDAQ:CLDX) shares to $100 from $90, maintaining a Buy rating due to the promising outlook for its drug, barzolvolimab. The firm's analysis, ahead of the pivotal EMBARQ-CSU1/2 trial results expected in October 2026, projects approximately $3 billion in peak global sales for the drug. Despite the stock trading above its Fair Value, Guggenheim assigns an 85% probability of success for the trial, anticipating significant upside.
Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating
Morgan Stanley has revised its price target for Celldex Therapeutics (NASDAQ:CLDX) to $40, down from the previous $44. Despite this adjustment, the firm has decided to maintain its Overweight rating on the stock.
Celldex CFO Sam Martin to Retire; Company Begins Search for Successor
Celldex Senior Vice President and Chief Financial Officer Sam Martin announced his retirement, effective on or about March 31, 2027. The company has initiated a search for his successor. Martin joined Celldex in April 2009 and has served as CFO since July 2017.
Celldex CFO Sam Martin to retire in March 2027 By Investing.com
Sam Martin, Celldex Therapeutics' Senior Vice President and Chief Financial Officer, announced his retirement effective March 2027. Martin has been with the company's finance team since 2009 and served as CFO since 2017, overseeing a period of strong financial health. Celldex, which develops antibody-based treatments, is currently searching for his replacement and anticipates data readouts from two Phase 3 barzolvolimab trials later this year, with recent positive analyst ratings and stock performance.
Celldex Starts CFO Search as Martin Plans 2027 Retirement
Celldex (NASDAQ:CLDX) announced that its Senior Vice President and Chief Financial Officer, Sam Martin, plans to retire in March 2027. Martin, who has served as CFO since 2017 and has been with Celldex since 2009, will remain in his role during the search for a successor to ensure a smooth transition. The company highlighted its robust pipeline and upcoming key data readouts from two Phase 3 barzolvolimab trials expected later in 2026, assuring investors that the CFO transition does not impact its late-stage programs.
Celldex Announces Planned Transition of Chief Financial Officer
Celldex announced that Sam Martin, Senior Vice President and Chief Financial Officer, plans to retire in 2027. Mr. Martin, who has been with Celldex since 2009 and CFO since 2017, will remain in his role until March 2027 to ensure a smooth transition while the company searches for his successor. The company expressed gratitude for his contributions and confidence in its future with a robust pipeline and upcoming data readouts.
Celldex Therapeutics (NASDAQ: CLDX) CFO to retire around March 2027
Celldex Therapeutics announced that its Senior Vice President and Chief Financial Officer, Sam Martin, plans to retire around March 31, 2027. Martin, who has been with the company since 2009 and CFO since 2017, will remain in his role until his successor is appointed to ensure a smooth transition. The company has initiated a search for a new Chief Financial Officer.
Celldex Announces Planned Transition of Chief Financial Officer
Celldex announced that Sam Martin, Senior Vice President and Chief Financial Officer, plans to retire in 2027. Mr. Martin, who has been with Celldex since 2009 and CFO since 2017, will remain until March 2027 to ensure a smooth transition while the company searches for his successor. The company highlighted his significant contributions to its growth from an early-stage R&D firm to a leading immunology company.
Celldex Therapeutics, Inc. Announces Retirement of Sam Martin as Chief Financial Officer, Effective on or About March 31, 2027
Celldex Therapeutics, Inc. announced that Sam Martin, their Senior Vice President and Chief Financial Officer, plans to retire around March 31, 2027. Martin has been with Celldex since 2009 and served as CFO since 2017. The company has initiated a search for his successor, and Martin will remain in his role until his retirement to ensure a smooth transition.
